Navigation Links
Progress on HIV/AIDS significant but insufficient

United Nations Secretary-General Kofi Annan shared his hope with a gathering of senior world officials at Headquarters that the 2001 Declaration of Commitment on HIV/AIDS would have heralded a response that matched the epidemic's scale, yet progress had been "significant but insufficient".

Citing achievements in the core areas of political leadership, funding, the intensity and reach of prevention programmes, and the availability of drug therapies, he said, however, that last year saw more new infections and more AIDS-related deaths than ever before. With the epidemic expanding at an accelerating rate and on every continent, treatment and prevention efforts were "nowhere near enough". For example, only 12 per cent of the people in need of antiretroviral therapies in low- and middle-income countries were receiving them.

He called for increased resources, better planning, better and more vocal leadership, and real investment in the empowerment of women and girls. Women now accounted for about half of all people living with HIV worldwide, but they were also the most courageous and creative champions in that fight. How the international community fared in the fight was crucial; only by meeting the challenge could it succeed in its efforts to build a humane, healthy and equitable world.

General Assembly President Jean Ping (Gabon) said that the HIV/AIDS threat in 2005 was much greater than when the Assembly met here four years ago. In every way, that threat had attained alarming proportions. In fact, he said, in 2004, the number of infected people had grown to about 5 million, and the number who had died had also grown, to 3.1 million in 2004, much more than for the four preceding years. The pandemic had also grown disturbingly worldwide, affecting new countries and new populations within countries, particularly women and girls, and 95 per cent of those infected were in low- and medium-income countries.

Given the quantum worsening in the ep
'"/>

Source:United Nations


Page: 1 2 3 4

Related biology news :

1. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
2. AIDS Public Awareness Campaign Expands Following Report Of Rapidly Progressive HIV
3. Progress being made in exploring potential use of stem cells to treat heart disease
4. Progress made in HIV vaccine development
5. Progress toward artificial photosynthesis?
6. New therapy for HIV/AIDS eliminates needles and excessive toxicity
7. South Africa still debating how to tackle HIV/AIDS when 5 million are infected
8. AIDS expert says global strategy needed to combat feminization of HIV/AIDS
9. HIV/AIDS rates in Tijuana, Mexico increasing at alarming rate
10. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy
11. Study defines effective microbicide design for HIV/AIDS prevention
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Progress HIV AIDS significant but insufficient

(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... report on a new way of preventing potentially harmful plasticizers ... migrating from one of the most widely used groups of ... polyvinyl chloride (PVC) plastics that are safer than those now ... say. Their study is in ACS, Macromolecules , a ...
... 2, 2010 -- A hormone responsible for the body,s stress ... in the pancreas, according to JDRF- funded researchers at the ... are the latest advances to underscore the potential for regeneration ... 1 diabetes. The research, which was published ...
... North Carolina State University have developed a "smart coating" that ... off infection. When patients have hip, knee or dental ... reject the implant. But the smart coating developed at NC ... implant. The coating creates a crystalline layer next to the ...
Cached Biology News:JDRF-funded research advances potential for regeneration as a possible cure for type 1 diabetes 2Smart coating opens door to safer hip, knee and dental implants 2
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... 19, 2014 Decision Resources Group finds that ... a 12 percent compound annual growth rate through 2023. ... population and the increasing adoption of dental implants. Growing ... will also spur demand for dental biomaterials because they ... periodontal treatments. Other key findings from Decision ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... , , , SOUTH SAN ... RIGL ) today announced the pricing of an underwritten public offering ... the public of $7.25 per share. All of the shares are ... up to an additional 1,950,000 shares to cover over-allotments, if any. ...
... , HAYWARD, Calif., Sept. 17 Intarcia ... study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of ... upon the successful completion of a 28-day phase 1b study of ITCA ... to evaluate the doses achieving the best results in the phase 1b ...
... DIEGO, Sept. 16 Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), ... San Diego, California, the stockholders re-elected the incumbent four-person Board of ... ratified the appointment of Squar, Milner, Peterson, ... ending March 31, 2010; , approved ...
Cached Biology Technology:Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock 2Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 2Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 3Aethlon Medical, Inc. Announces Annual Meeting Results 2Aethlon Medical, Inc. Announces Annual Meeting Results 3
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Request Info...
... Polyoxyethylene Lauryl Ether 30% ... Kathon Preservative. Surfactant. Clear ... immunohistochemistry is 1 mL ... solution added to 400 ...
Biology Products: